Product logins

Find logins to all Clarivate products below.


Prostate Cancer | Disease Landscape & Forecast | G7 | 2023

Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), impacting current treatment of nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer (HSPC). Continued development of the hormonal therapies, plus the development of targeted agents (e.g., Janssen / GlaxoSmithKline’s Zejula, Pfizer’s Talzenna), antibody-drug conjugates (MacroGenics’ vobramitamab duocarmazine), and novel prostate-specific membrane antigen (PSMA)-targeted radioligands (e.g., Novartis’s Pluvicto and POINT Biopharma’s 177Lu-PNT2002) will drive robust market growth over the 2022-2032 forecast period.

QUESTIONS ANSWERED

  • What are the sizes of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates change over time?
  • What are the key drivers and constraints in the prostate cancer market, and how will the major markets evolve over the 10-year forecast period?
  • What is the current state of treatment for prostate cancer? What are interviewed experts’ insights on these treatment options?
  • What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning and uptake in the market?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Related Market Assessment Reports

Report
Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…
Report
Prostate Cancer – Unmet Need – Unmet Need – Metastatic Hormone-Sensitive Prostate Cancer (US/EU)
Prostate cancer is the second-most-prevalent cancer in men, significantly impacting male mortality rates. Hormonal therapy is a cornerstone of drug treatment for all stages of prostate cancer…
Report
Prostate Cancer | Disease Landscape & Forecast | G7 | 2024
Hormonal agents are routinely used in all lines of therapy and thus dominate the treatment of prostate cancer. Next-generation hormonal treatments have expanded beyond metastatic castrate-resistant…
Report
Prostate Cancer – Geographic focus: China – China In-Depth – Prostate Cancer
The treatment of prostate cancer in China is undergoing a transformative phase, characterized by an increase in diagnosed incident cases due to improved screening techniques. This shift is…
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in Breast Cancer, Ovarian Cancer, and Prostate Cancer (US)
Biomarker-driven prescribing is paramount in key oncology indications, particularly breast cancer, ovarian cancer, and prostate cancer. Key to all three indications are PARP inhibitors, such as…